Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 4/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896008 | 1.00 | EGFR (0.65) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16895541 | 0.91 | EGFR (0.77) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16895542 | 0.91 | EGFR (0.77) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16896194 | 0.89 | EGFR (0.64) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16896195 | 0.89 | EGFR (0.64) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16901717 | 0.89 | EGFR (0.78) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16895485 | 0.89 | EGFR (0.63) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16895483 | 0.89 | EGFR (0.63) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16895846 | 0.88 | EGFR (0.82) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 | |
| SCHEMBL16896054 | 0.88 | EGFR (0.82) | EGFRCYP3A4CYP2C9MAP3K7IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257848-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | Novartis AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2773635-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2773635-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9440957-B2 | Compounds and compositions for modulating EGFR Activity | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | disclosed |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP3A4 4848/4885CYP2C9 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.